Institutes
Refine
Year of publication
Document Type
- Doctoral Thesis (285)
- Article (268)
- Preprint (38)
- Contribution to a Periodical (25)
- Book (13)
- Report (2)
Language
- English (490)
- German (140)
- Multiple languages (1)
Has Fulltext
- yes (631)
Is part of the Bibliography
- no (631)
Keywords
- RNA (11)
- SARS-CoV-2 (10)
- NMR spectroscopy (9)
- photochemistry (9)
- NMR (8)
- inflammation (8)
- Cell biology (7)
- Biochemistry (6)
- E2 enzyme (6)
- TRACT (6)
Institute
- Biochemie, Chemie und Pharmazie (631)
- Präsidium (38)
- Medizin (32)
- Buchmann Institut für Molekulare Lebenswissenschaften (BMLS) (30)
- Zentrum für Biomolekulare Magnetische Resonanz (BMRZ) (29)
- Biowissenschaften (22)
- MPI für Biophysik (14)
- Physik (11)
- Zentrum für Arzneimittelforschung, Entwicklung und Sicherheit (4)
- Exzellenzcluster Makromolekulare Komplexe (3)
The retinoid X receptor (RXR) is a ligand-sensing transcription factor acting mainly as a universal heterodimer partner for other nuclear receptors. Despite presenting as a potential therapeutic target for cancer and neurodegeneration, adverse effects typically observed for RXR agonists, likely due to the lack of isoform selectivity, limit chemotherapeutic application of currently available RXR ligands. The three human RXR isoforms exhibit different expression patterns; however, they share high sequence similarity, presenting a major obstacle toward the development of subtype-selective ligands. Here, we report the discovery of the saturated fatty acid, palmitic acid, as an RXR ligand and disclose a uniform set of crystal structures of all three RXR isoforms in an active conformation induced by palmitic acid. A structural comparison revealed subtle differences among the RXR subtypes. We also observed an ability of palmitic acid as well as myristic acid and stearic acid to induce recruitment of steroid receptor co-activator 1 to the RXR ligand-binding domain with low micromolar potencies. With the high, millimolar endogenous concentrations of these highly abundant lipids, our results suggest their potential involvement in RXR signaling.
Guanosine triphosphate (GTP) cyclohydrolase I (GCH1) catalyzes the conversion of GTP to dihydroneopterin triphosphate (H2NTP), the initiating step in the biosynthesis of tetrahydrobiopterin (BH4). Besides other roles, BH4 functions as cofactor in neurotransmitter biosynthesis. The BH4 biosynthetic pathway and GCH1 have been identified as promising targets to treat pain disorders in patients. The function of mammalian GCH1s is regulated by a metabolic sensing mechanism involving a regulator protein, GCH1 feedback regulatory protein (GFRP). GFRP binds to GCH1 to form inhibited or activated complexes dependent on availability of cofactor ligands, BH4 and phenylalanine, respectively. We determined high-resolution structures of human GCH1−GFRP complexes by cryoelectron microscopy (cryo-EM). Cryo-EM revealed structural flexibility of specific and relevant surface lining loops, which previously was not detected by X-ray crystallography due to crystal packing effects. Further, we studied allosteric regulation of isolated GCH1 by X-ray crystallography. Using the combined structural information, we are able to obtain a comprehensive picture of the mechanism of allosteric regulation. Local rearrangements in the allosteric pocket upon BH4 binding result in drastic changes in the quaternary structure of the enzyme, leading to a more compact, tense form of the inhibited protein, and translocate to the active site, leading to an open, more flexible structure of its surroundings. Inhibition of the enzymatic activity is not a result of hindrance of substrate binding, but rather a consequence of accelerated substrate binding kinetics as shown by saturation transfer difference NMR (STD-NMR) and site-directed mutagenesis. We propose a dissociation rate controlled mechanism of allosteric, noncompetitive inhibition.
Release of neuropeptides from dense core vesicles (DCVs) is essential for neuromodulation. Compared to the release of small neurotransmitters, much less is known about the mechanisms and proteins contributing to neuropeptide release. By optogenetics, behavioral analysis, electrophysiology, electron microscopy, and live imaging, we show that synapsin SNN-1 is required for cAMP-dependent neuropeptide release in Caenorhabditis elegans hermaphrodite cholinergic motor neurons. In synapsin mutants, behaviors induced by the photoactivated adenylyl cyclase bPAC, which we previously showed to depend on acetylcholine and neuropeptides (Steuer Costa et al., 2017), are altered like in animals with reduced cAMP. Synapsin mutants have slight alterations in synaptic vesicle (SV) distribution, however, a defect in SV mobilization was apparent after channelrhodopsin-based photostimulation. DCVs were largely affected in snn-1 mutants: DCVs were ∼30% reduced in synaptic terminals, and not released following bPAC stimulation. Imaging axonal DCV trafficking, also in genome-engineered mutants in the serine-9 protein kinase A phosphorylation site, showed that synapsin captures DCVs at synapses, making them available for release. SNN-1 co-localized with immobile, captured DCVs. In synapsin deletion mutants, DCVs were more mobile and less likely to be caught at release sites, and in non-phosphorylatable SNN-1B(S9A) mutants, DCVs traffic less and accumulate, likely by enhanced SNN-1 dependent tethering. Our work establishes synapsin as a key mediator of neuropeptide release.
Das Hepatozelluläre Karzinom (HCC) ist die sechsthäufigste Krebsart mit der zweithäufigsten krebsbedingten Letalität. Sorafenib ist bereits seit über 10 Jahren die einzige verfügbare und zugelassene systemische Chemotherapie. Allerdings zeigen Patienten oft eine Resistenz gegenüber Sorafenib.
In zahlreichen Krebsarten konnte bereits gezeigt werden, dass Sphingolipide bei der Tumorentwicklung und Chemoresistenz eine wichtige Rolle spielen. Sphingolipide sind bioaktive Lipidmoleküle, welche unteranderem für die Beeinflussung verschiedener Signalwege intra- und extrazellulär verantwortlich sind. So konnte gezeigt werden, dass das Verhältnis zwischen Sphingosin-1-Phosphat (S1P) und Ceramiden eine wichtige Rolle für das Überleben von Zellen spielt, wobei eine Verschiebung des Verhältnisses zugunsten des S1P meist eine proliferative Wirkung auf Zellen hat. Für die Phosphorylierung des Sphingosins zu S1P sind die zwei Enzyme Sphingosinkinase 1 und 2 (SPHK1/2) verantwortlich.
Es gibt bereits Studien, die nachweisen konnten, dass diese Enzyme gerade in Tumorzellen verstärkt exprimiert werden. Auf der anderen Seite kann eine verstärkte Bildung von Ceramiden die Apoptose der Tumorzellen verstärken. Daher ist es nicht verwunderlich, dass der Sphingolipid-Stoffwechsel einen interessanten Angriffspunkt für die Krebstherapie darstellt. Aus diesem Grund sollte in der vorliegenden Arbeit zunächst untersucht werden, ob Sorafenib einen Einfluss auf den Sphingolipid Stoffwechsel hat. Weiter sollte untersucht werden, ob die Beeinflussung des Sphingolipid-Stoffwechsels die Effekte von Sorafenib potenzieren könnte.
Es konnte zunächst gezeigt werden, dass Sorafenib die mRNA-Expression verschiedener Enzyme, die das Verhältnis zwischen Ceramiden und S1P regulieren, beeinflussen kann. Es wurde weiter untersucht, wie sich der Ceramidsynthase Inhibitor FB1 auf die Proliferation und die Induktion der Apoptose auswirkt. Dies wurde ebenfalls mit SLP (SPHK1 Inhibitor), SLM (SPHK2 Inhibitor) und SKI II, einem unspezifischen Inhibitor beider Sphingosinkinasen, untersucht. Es wurden weiter die Einflüsse aller verwendeten Substanzen auf die Bildung verschiedener Sphingolipide untersucht.
Hierbei konnte gezeigt werden, dass Sorafenib in der Lage ist, die Proliferation der Zellen zu hemmen und die Apoptose-Induktion zu fördern. Weiter führte Sorafenib zu einer Akkumulation der Dihydroceramide. Was wiederrum weder mit SKI II, FB1; SLP noch SLM beobachtet werden konnte. Der signifikante Anstieg der Dihydroceramid-Konzentrationen konnte mit dem durch Sorafenib induzierten oxidativen Stress in Verbindung gebracht werden.
SLP und SLM waren nicht in der Lage, die Effekte von Sorafenib auf die Proliferation zu potenzieren. Die Kombination von Sorafenib mit SLP oder SLM führte jedoch in den Huh7.5 Zellen zu einer drastischen Reduktion des S1P-Spiegel.
FB1 und SKI II führten zu einer stärkeren Hemmung der Proliferation als Sorafenib. Wobei gezeigt werden konnte, dass beide Substanzen die Ceramid-Spiegel tendenziell eher vermindern und die S1P-Spiegel erhöhen. Durch die Stimulation mit FB1 kam es sogar zu einer signifikanten Erhöhung der S1P-Spiegel. Es scheint, dass der Einfluss von FB1 und SKI II auf die Proliferation der Zellen unabhängig vom Sphingolipid-Stoffwechsel ist. Diese scheinen eher über andere Mechanismen zu wirken. Es könnte von Interesse sein, gerade diese Signalwege von SKI II im HCC weiter zu untersuchen, da SKI II bereits in Mausmodellen anderer Krebsarten vielversprechende Ergebnisse zeigte.
The post-transcriptional modification of the canonical nucleoside uridine into its rotational isomer pseudouridine occurs in non-coding as well as coding RNA and is the most abundant post-transcriptional modification in all kingdoms of life. While the occurrence of pseudouridine has been linked to the enhancement of stability and the codon-anticodon interaction in tRNAs, enhancement of the translation efficiency in rRNAs, regulatory functions in spliceosomal snRNA and nonsense codon suppression in mRNA, its exact role in many RNAs is still ambiguous. The uridine to pseudouridine isomerization can either be catalyzed by one of various standalone pseudouridylases or it can be performed in an RNA-guided manner by H/ACA ribonucleoproteins. In eukaryotes, the guide RNA always adapts a conserved bipartite, double-hairpin conformation. Each hairpin contains an internal RNA-loop motif, which can recruit a specific substrate RNA via base pairing. The catalytically active RNP is formed by the interactions of the guide RNA with four proteins. While Cbf5 forms the catalytically active center, Nop10 and Nhp2 perform auxiliary functions and Gar1 is involved in substrate turnover. Up until now, most structural knowledge about H/ACA RNPs has been derived from archaeal complexes, while the exact structure-function-relationships between RNA and proteins in eukaryotic RNPs is still ambiguous. While archaeal H/ACA RNPs share many similarities with eukaryotic RNPs and act as good model system, there are also many differences between them like eukaryotic specific protein domains as well as the overall bipartite complex structure, dictated by the snoRNA. Investigating pseudouridylation by eukaryotic H/ACA RNPs opens up a broad area of research and helps to gain a better understanding of this enzyme class – especially since malfunction of H/ACA RNPs has been linked to the genetic disease Dyskeratosis congenita as well as several types of cancer.
The main goal of this thesis was to gain new insights into the RNA/protein interactions in the eukaryotic snR81 H/ACA snoRNP from Saccharomyces cerevisiae on a structural as well as dynamical level. In the first part of this thesis, the main goal was to in vitro prepare a functionally active snR81 H/ACA RNP. The guiding snoRNA was prepared by in vitro transcription and purification, while the Saccharomyces cerevisiae proteins were recombinantly expressed from Escherichia coli. Apart from the full length, bipartite snR81 snoRNP, several sub-complexes of the RNP were reconstituted. Therefore, snoRNA constructs were designed and prepared, which only contained a single hairpin motif of the complex. Furthermore, snoRNA constructs in which the apical hairpin stem was replaced by a stable tetraloop were prepared, to investigate the influence of the apical stem on protein binding and activity. Also, for the eukaryotic proteins, a shortened version of Gar1 (Gar1Δ) was utilized, which lacks the eukaryotic specific RGG domains, that have been characterized as accessory RNA binding motifs. Reconstituted snoRNPs were utilized in catalytic activity assays, monitoring the turnover rate of uridine to pseudouridine. For this purpose, radioactively labeled substrate RNAs were prepared by phosphorylation and splinted ligation of oligonucleotides and were objected to reconstituted H/ACA RNPs under single as well as multiple turnover conditions. In the second part of this thesis, the RNA/protein interactions were dissected via single molecule FRET spectroscopy. Therefore, the snoRNA was labeled with an acceptor fluorophore via NHS ester/amine-reaction. Furthermore, the snoRNA contained a biotin-handle, allowing immobilization of the complex during the experimental time-window of the spectroscopic analysis. Eukaryotic specific protein Nhp2 was labeled with a donor fluorophore via “click” chemistry, which included the chemical synthesis and incorporation by genetic code expansion of non-canonical amino acids. The interactions of Nhp2 with the different snoRNA constructs (standalone-hairpins “H5” and “H3”, as well as hairpins lacking the apical binding motif “H5Δ” and “H3Δ”) were monitored on a single molecule level.
In summary, it was possible to gain new insights into the complex structure and the dynamical behavior of the still sparsely characterized eukaryotic H/ACA RNPs. Especially, new knowledge could be obtained about the hairpin specific behavior on the bipartite RNA complex structure, including the rather ambiguous role of the protein Nhp2 and the contribution of the eukaryotic specific features of Gar1 in their interaction with the guide/substrate RNA.
In vitro release testing as an alternative to establishing bioequivalence of drug products in vivo
(2020)
Generische Arzneimittel werden als Arzneimittel definiert, die im Vergleich zu einem Referenzarzneimittel hinsichtlich der meisten pharmazeutischen Aspekte identisch sind.
Um die therapeutische Äquivalenz zum Referenzprodukt sicherzustellen, sind Bioverfügbarkeitsstudien erforderlich. Für Arzneimittel, die als feste, perorale, schnell freisetzende Darreichungsformen formuliert sind, kann auf den Nachweis der Bioäquivalenz in vivo zugunsten eines vergleichenden Freisetzungstests in vitro im Rahmen eines sogenannten Biopharmaceutics Classification System (BCS) basierten Biowaivers verzichtet werden.
Der BCS-basierte Biowaiver ist ein vielversprechendes Instrument, welches Kosteneinsparungen sowie eine Verringerung des regulatorischen Aufwands im Zuge der behördlichen Zulassung von Generika ermöglicht und dazu beitragen kann, die Zugänglichkeit unentbehrlicher Arzneimittel zu verbessern. Dabei gibt es jedoch auch Hürden, welche die weitläufige Anwendung des Verfahrens verhindern: Unklare Löslichkeits- und Permeabilitätsklassifizierungen von Wirkstoffen, Arzneimittel, welche die in vitro Freisetzungskriterien nicht erfüllen, sowie Zweifel an der Eignung der regulatorischen Spezifikationen, Freisetzungsunterschiede in vitro erfassen zu können, die für das Verhalten in vivo relevant sind.
In der vorliegenden Dissertation werden diese Probleme thematisiert, indem eine umfassende Bewertung der Anwendbarkeit und Einschränkungen des BCS-basierten Biowaivers in seinem aktuell regulatorisch vorgeschriebenen Ablauf vorgenommen wird. Mögliche Anpassungen des Verfahrens wurden auf der Grundlage experimenteller in vitro Daten untersucht, bewertet und mithilfe von in silico Simulationsmodellen auf die Situation in vivo extrapoliert.
Throughout their life cells of eukaryotic organisms can be confronted with a variety of proteotoxic stresses and in order to survive, corresponding resistance mechanisms had to evolve. Proteotoxic stresses can cause misfolding of proteins and accumulation of toxic protein aggregates. Failure to remove aggregates of misfolded proteins compromises cellular function and can ultimately cause cell death and disease. To deal with this challenge, cells utilize a complex network of protein quality control pathways, including chaperones, the ubiquitin-proteasome system and the autophagy system.
Another mechanism to cope with proteotoxic stresses is the stalling of translation initiation in order to save valuable resources and prevent faulty translation. Upon stress, intrinsically disordered RNA-binding proteins such as TIA-1 or G3BP1/2 are recruited to stalled preinitiation complexes and a network of multivalent interactions between RNAs and proteins is formed. These mRNP networks can merge with each other and phase separate into membraneless liquid-like structures called stress granules (SGs). Once stress is released, SGs are quickly resolved and translation continues. Yet, chronic stress or mutations of SG-associated proteins can cause persistent SGs, which can sequester misfolded proteins and have been linked to neurodegenerative diseases such as amyotrophic lateral sclerosis or frontotemporal dementia.
In mammalian cells, three isoforms of the small ubiquitin-related modifier (SUMO), SUMO1, SUMO2 and SUMO3 are covalently attached to lysine residues of target proteins. SUMO conjugation is catalyzed via an enzymatic cascade of an heteromeric E1 activating enzyme, the E2 conjugating enzyme Ubc9 and in some cases one of a limited number of E3 SUMO ligases. SUMOylation is a dynamic modification and can be reversed by SUMO isopeptidases, the best characterized of which belong to the SENP family. Cellular stresses such as heat or oxidative stress strongly induce SUMOylation resulting in increased numbers of poly-SUMOylation (formation of SUMO2/3 chains) on nuclear proteins.
The SUMO-targeted ubiquitin ligase (STUbL) RNF4 harbors four SUMO interaction motifs in its N-terminal domain. This feature allows RNF4 to specifically bind poly-SUMOylated proteins and catalyze their proteolytic or non-proteolytic ubiquitylation.
A variety of substrate proteins have been shown to undergo SUMO-primed ubiquitylation by RNF4 in response to stress or DNA damage. RNF4-mediated ubiquitylation is often a signal for proteolytic degradation of these substrates.
In this work we aimed by identify novel RNF4 targets, in heat-stressed cells in order to gain a wider understanding of the nuclear proteotoxic stress response. Analysis by mass spectrometry revealed that a large fraction of RNF4-interacting proteins in heatstressed cells are nuclear RNA-binding proteins, many of which shuttle outside the nucleus and associate with SGs upon stress. We validated, that nuclear RNA-binding proteins, such as TDP-43 and hnRNP M are indeed heat-induced targets of SUMOprimed ubiquitylation by RNF4.
These initial results led us to further investigate the links between the SUMO/RNF4-mediated, nuclear protein quality control and the dynamics of cytosolic heat- or arsenite-induced SGs. SUMO2/3 and RNF4 are mainly nuclear proteins and we confirmed that they do not associate with SGs. Yet, we could demonstrate that depletion of SUMO2/3, the E3 SUMO ligase PML or RNF4 as well as chemical inhibition of SUMOylation strongly delayed SG clearance upon stress release, indicating that a functional STUbL pathway is essential for the timely clearance of SGs.
Next, we investigated how stress-induced poly-SUMOylation is regulated. Our data shows that SENP levels and activities are reduced in response to heat and arsenite stress, which allows the buildup of poly-SUMO chains on nuclear proteins. Limitation of poly-SUMOylation by overexpression of the SUMO chain-specific isopeptidases SENP6 and SENP7 induced SG formation. In contrast, poly-SUMO-priming by chemical depletion of SENP6 with the drug hinokiflavone drastically limited SG formation upon stress treatment. These results indicate a clear role of chain-specific SENPs in the regulation of stress-induced poly-SUMOylation and SG dynamics.
Last, we investigated whether the STUbL pathway could affect the phase separation of FUSP525 (an ALS-linked mutant of the SG-associated protein FUS) and observed that perturbations of the STUbL pathway lead to an increased phase separation of FUSP525L.
Thus, our work connects the SUMO/RNF4 protein quality control mechanism to the dynamics of SGs supporting the hypothesis that release of proteotoxic stress in the nucleus facilitates the clearance of cytosolic SGs. Thereby, we discovered a previously unknown link between the nuclear and cytosolic axis of proteotoxic stress response.
In the past decade, tissue-resident innate lymphoid cells (ILC) have become a central field of immunological research. ILC are a family of innate immune cells comprising cytotoxic Natural Killer (NK) cells and the non-cytotoxic helper like ILC1, ILC2 and ILC3. They mirror the functions and phenotypes of T cells, but do not require rearranged antigen-specific receptors for their rapid response to signals from injured or infected tissue. As potent cytokine producers being enriched in mucosal tissue, ILC play an essential role in tissue maintenance and regulating immunity to chronic inflammation and infection (Vivier et al., 2018). Although heterogeneity and plasticity of ILC complicates their classification, the pathophysiology of a broad variety of autoimmune and chronic inflammatory diseases have been associated with dysregulations in ILC subset distribution and functions (Dzopalic et al., 2019). This highlights their importance in human health and disease and accounts for the need for markers unambiguously describing the different ILC subtypes. This work introduces NKp65, a C-type lectin-like receptor (CTLR) encoded in the natural killer gene complex by the KLRF2 gene, as an exclusive marker for human ILC3. NKp65 expression especially discerns ILC3-like NK cell precursor from mature NK cells which express the NKp65-relative NKp80. Moreover, flow cytometric analysis of NKp65 expression aids in the demarcation of natural cytotoxicity receptor (NCR) expressing ILC3, from the closely related but functionally distinct RORt+ LTi cells and NCR- ILC3. This work further provides insights into NK cell development by in vitro differentiation studies in which NKp65 expressing cells are generated in presence of OP9 feeder cells and cytokines to support development. In such cultures, NKp65 expressing in vitro ILC (ivILC) acquire NKp80 expression in a Notch-dependent manner indicating their differentiation into mature NK cells. Acquisition of NK cell phenotypic markers is accompanied by NKp65 downregulation which leads to the mutually exclusive expression of NKp80 on NK cells and NKp65 on ILC3-like cells. Further insights are provided into the functional consequences of NKp65 engagement by its cognate high affinity ligand ‘keratinocyte-associated C-type lectin’ (KACL) which is selectively expressed on human keratinocytes (Bauer et al., 2015; Spreu et al., 2010). Expressed on ivILC, NKp65 mediates killing of KACL expressing target cells, suggesting that NKp65-KACL interaction promotes cellular cytotoxicity. In this context, the observed metalloproteinase dependent shedding of NKp65 might play a role in the termination of the cellular interaction. The findings on the regulation of NKp65 expression demonstrate the presence of a functional STAT5 response element in the KLRF2 promoter endowing a transcriptional control of NKp65 expression by IL-7 signaling. This provides an interesting link between the dependency of ILC3 on IL-7 signaling for their maintenance and the specific expression of NKp65 on these cells.
In summary, this study provides new insights into the physiologic expression of the CTLR NKp65 on human ILC3. The dependency of NKp65 surface expression on sustained STAT5 signaling provided by IL-7 underlines the connection of NKp65 expression and an ILC3 phenotype which might contribute to promote future research in discerning the interspersed pathways of ILC3 and NK cell development. The tissue and cell specific expression of NKp65 on ILC3 and its ligand KACL on keratinocytes of the human skin further suggests an important role of this genetically coupled receptor-ligand pair in tissue specific immunosurveillance.
[Nachruf] Hugo Fasold
(2018)